Literature DB >> 21777638

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

Jorge E Osorio1, Claire Y-H Huang, Richard M Kinney, Dan T Stinchcomb.   

Abstract

Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned, fully sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21777638      PMCID： PMC4592106          DOI： 10.1016/j.vaccine.2011.07.020

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  46 in total

1.  Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

Authors:  Arunee Sabchareon; Jean Lang; Pornthep Chanthavanich; Sutee Yoksan; Rémi Forrat; Phanorsi Attanath; Chukiate Sirivichayakul; Krisana Pengsaa; Chanathep Pojjaroen-Anant; Watcharee Chokejindachai; Achara Jagsudee; Jean-François Saluzzo; Natth Bhamarapravati
Journal:  Am J Trop Med Hyg       Date:  2002-03       Impact factor: 2.345

2.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.

Authors:  Doris Apt; Kanakatte Raviprakash; Alice Brinkman; Andrey Semyonov; Shumin Yang; Craig Skinner; Lori Diehl; Richard Lyons; Kevin Porter; Juha Punnonen
Journal:  Vaccine       Date:  2005-08-10       Impact factor: 3.641

4.  Immunological enhancement of dengue virus replication.

Authors:  S B Halstead; J S Chow; N J Marchette
Journal:  Nat New Biol       Date:  1973-05-02

Review 5.  Dengue.

Authors:  Scott B Halstead
Journal:  Lancet       Date:  2007-11-10       Impact factor: 79.321

Review 6.  Prospects for a dengue virus vaccine.

Authors:  Stephen S Whitehead; Joseph E Blaney; Anna P Durbin; Brian R Murphy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 7.  Geographic expansion of dengue: the impact of international travel.

Authors:  Annelies Wilder-Smith; Duane J Gubler
Journal:  Med Clin North Am       Date:  2008-11       Impact factor: 5.456

8.  Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Authors:  Wellington Sun; Dennis Cunningham; Steven S Wasserman; Judith Perry; J Robert Putnak; Kenneth H Eckels; David W Vaughn; Stephen J Thomas; Niranjan Kanesa-Thasan; Bruce L Innis; Robert Edelman
Journal:  Hum Vaccin       Date:  2009-01-27

9.  A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.

Authors:  Kanakatte Raviprakash; Danher Wang; Dan Ewing; David H Holman; Karla Block; Jan Woraratanadharm; Lan Chen; Curtis Hayes; John Y Dong; Kevin Porter
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

Review 10.  Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.

Authors:  Scott B Halstead; Suresh Mahalingam; Mary A Marovich; Sukathida Ubol; David M Mosser
Journal:  Lancet Infect Dis       Date:  2010-10       Impact factor: 25.071
View more
  48 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

2.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

3.  Prospects for a dengue vaccine: progress and pitfalls.

Authors:  Sarah L George
Journal:  Mo Med       Date:  2014 Jul-Aug

4.  Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.

Authors:  Elizabeth A Dietrich; Yee Tsuey Ong; Janae L Stovall; Hansi Dean; Claire Y-H Huang
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

Review 5.  Vaccines licensed and in clinical trials for the prevention of dengue.

Authors:  J Torresi; G Ebert; M Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

6.  CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.

Authors:  Haiyan Chu; Sarah L George; Dan T Stinchcomb; Jorge E Osorio; Charalambos D Partidos
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

7.  Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice.

Authors:  Jeremy Fuchs; Haiyan Chu; Peter O'Day; Richard Pyles; Nigel Bourne; Subash C Das; Gregg N Milligan; Alan D T Barrett; Charalambos D Partidos; Jorge E Osorio
Journal:  Vaccine       Date:  2014-09-17       Impact factor: 3.641

8.  Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.

Authors:  Jesica A Swanstrom; Sandra Henein; Jessica A Plante; Boyd L Yount; Douglas G Widman; Emily N Gallichotte; Hansi J Dean; Jorge E Osorio; Charalambos D Partidos; Aravinda M de Silva; Ralph S Baric
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

9.  Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.

Authors:  Ge Liu; Langzhou Song; David W C Beasley; Robert Putnak; Jason Parent; John Misczak; Hong Li; Lucia Reiserova; Xiangyu Liu; Haijun Tian; Wenzhe Liu; Darlene Labonte; Lihua Duan; Youngsun Kim; Linda Travalent; Devin Wigington; Bruce Weaver; Lynda Tussey
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

10.  Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

Authors:  Jorge E Osorio; Ivan D Velez; Cynthia Thomson; Liliana Lopez; Alejandra Jimenez; Aurelia A Haller; Shawn Silengo; Jaclyn Scott; Karen L Boroughs; Janae L Stovall; Betty E Luy; John Arguello; Mark E Beatty; Joseph Santangelo; Gilad S Gordon; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Lancet Infect Dis       Date:  2014-07-23       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.